ChemoCentryx, Vifor in deal for rare renal disease candidate

ChemoCentryx Inc. (NASDAQ:CCXI) rose $0.89 (42%) to $2.99 on Tuesday after it granted the Vifor Pharma Ltd. subsidiary of Galenica Ltd. (SIX:GALN) exclusive rights

Read the full 243 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE